Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

10.07USD
19 Jul 2018
Change (% chg)

$-0.18 (-1.76%)
Prev Close
$10.25
Open
$10.14
Day's High
$10.30
Day's Low
$9.98
Volume
114,554
Avg. Vol
287,191
52-wk High
$31.42
52-wk Low
$6.99

Latest Key Developments (Source: Significant Developments)

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

Dermira reports Q2 loss per share $0.89
Monday, 8 Aug 2016 

Dermira Inc : Dermira reports second quarter 2016 financial results and provides corporate update . Says continues to estimate GAAP operating expenses of $110-120 million for 2016 . Dermira Inc qtrly loss per share $0.89 .Says now expects GAAP operating expenses to be at upper end of range of $110-120 million for 2016.  Full Article

Photo

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.